1144 related articles for article (PubMed ID: 33653121)
1. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Focus (Am Psychiatr Publ); 2022 Apr; 20(2):241-251. PubMed ID: 37153136
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
4. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
5. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
7. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
9. Disentangling the association of depression on the anti-fatigue effects of ketamine.
Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
[TBL] [Abstract][Full Text] [Related]
12. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
14. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
Price RB; Spotts C; Panny B; Griffo A; Degutis M; Cruz N; Bell E; Do-Nguyen K; Wallace ML; Mathew SJ; Howland RH
Am J Psychiatry; 2022 Dec; 179(12):959-968. PubMed ID: 36128684
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
17. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
18. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
19. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
20. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]